Biopure Announces Meeting With FDA(nce or additional issues raised at alate...),Health

Date:7/7/2008

nce or additional issues raised at a later date, unexpected costs and expenses, delays and adverse determinations by regulatory authorities, unanticipated problems with the product's commercial use, whether or not product related, and with product distributors, sales agents or other third parties, delays in clinical trials, and the other factors identified under the heading "Risk Factors" in the Company's quarterly report on Form 10-Q filed on June 16, 2008, as amended on June 18, 2008, which can be accessed in the EDGAR database at the U.S. Securities and Exchange Commission's (SEC) website, http://www.sec.gov. The company undertakes no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances arising after the date hereof. A full discussion of the company's operations and financial condition can be found in the company's filings with the SEC.

Contact: Tiana Gorham

Biopure Corporation

(617) 234-6826

IR@biopure.com

'/>"/>

SOURCE Biopure Corporation Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related medicine technology :

1. Biopure Phase III Orthopedic Trial Results Published in Journal of Trauma
2. Biopure Announces Publication of Phase II Proof-of-Concept Coronary Trial
3. Biopure Reports on Meeting with the FDA
4. Biopure Announces 2007 Third Quarter Financial Results
5. Biopure Seeks Compassionate Use Protocol for Treatment of Acute Anemia
6. BD Announces CE Marking of a New Molecular Test to Diagnose Patients with Clostridium difficile Infections
7. Applisonix Announces Breakthrough in Ultrasound Technology for Hair Removal - Average Hair Reduction of 38% Following Initial Treatment
8. Silence Therapeutics Announces Board Changes
9. ADVENTRX Announces Preliminary Response Rate Data From Discontinued Phase 3 Trial of CoFactor(R)
10. Halozyme Therapeutics Announces That Chemophase Meets Primary Endpoint in Phase I/IIa Clinical Trial
11. Emisphere Technologies Announces the Launch of a Human Clinical Trial For Oral Parathyroid Hormone (PTH)